Skip to Main Content

Paper Details

A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Invest New Drugs
6
2022
Author NameAffiliation
Al B BensonNorthwestern University
  • 1 - 1

Datasets

Release 1.2